The microbial community of the skin influences the function and development of the immune system, thus potentially participating in the pathophysiology of several important diseases of the skin including atopic dermatitis. Since normal microbial communities exist in equilibrium with the host, we have sought to better understand the mechanisms by which the microbiome controls mammalian immune responses. We have discovered that it was wrong to assume that the cutaneous microbiome is separated from dermal cells by the epidermis. Strong evidence now shows that microbial communities are in equilibrium across the basement membrane zone and populate the dermal stroma. These observations demonstrate that our microbiome can directly interact with dermal immunocytes, thus positioning these bacteria in a way to control immune function. Furthermore, this shows how barrier functions of the skin can influence the interaction between the microbiome and immunocytes. This conclusion provides the basis of the general hypothesis of this project that skin barrier function abnormalities in atopic dermatitis result in the abnormal entry of bacteria into the dermis, and this lack of normal barrier function drives an immune response characteristic of AD. This animal study seeks to address 2 fundamental questions: 1) Is the entry of microbes into the dermis altered in atopic dermatitis? and 2) How do these changes in the entry and identity of the dermal microbiome alter skin immune function? The specific aims of this project are:
Aim 1 : Determine how the entry of the surface microbiome is altered in mouse models of AD.
Aim 2 : Evaluate how the entry of specific bacteria into the dermis alters immune responses.
Aim 3 : Test how bacterial entry into the dermis modifies susceptibility to infection in AD.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI117673-03
Application #
9256429
Study Section
Special Emphasis Panel (ZAI1-ZL-I)
Project Start
Project End
Budget Start
2017-04-01
Budget End
2018-03-31
Support Year
3
Fiscal Year
2017
Total Cost
$213,024
Indirect Cost
Name
National Jewish Health
Department
Type
Independent Hospitals
DUNS #
076443019
City
Denver
State
CO
Country
United States
Zip Code
80206
Li, Jin; Zheng, Le; Uchiyama, Akihiko et al. (2018) A data mining paradigm for identifying key factors in biological processes using gene expression data. Sci Rep 8:9083
Malhotra, Nidhi; Leyva-Castillo, Juan Manuel; Jadhav, Unmesh et al. (2018) ROR?-expressing T regulatory cells restrain allergic skin inflammation. Sci Immunol 3:
Bin, Lianghua; Li, Xiaozhao; Richers, Brittany et al. (2018) Ankyrin repeat domain 1 regulates innate immune responses against herpes simplex virus 1: A potential role in eczema herpeticum. J Allergy Clin Immunol 141:2085-2093.e1
Dyjack, Nathan; Goleva, Elena; Rios, Cydney et al. (2018) Minimally invasive skin tape strip RNA sequencing identifies novel characteristics of the type 2-high atopic dermatitis disease endotype. J Allergy Clin Immunol 141:1298-1309
Archer, Nathan K; Jo, Jay-Hyun; Lee, Steven K et al. (2018) Injury, dysbiosis, and filaggrin deficiency drive skin inflammation through keratinocyte IL-1? release. J Allergy Clin Immunol :
Leyva-Castillo, Juan Manuel; Yoon, Juhan; Geha, Raif S (2018) IL-22 promotes allergic airway inflammation in epicutaneously sensitized mice. J Allergy Clin Immunol :
Nakatsuji, Teruaki; Chen, Tiffany H; Butcher, Anna M et al. (2018) A commensal strain of Staphylococcus epidermidis protects against skin neoplasia. Sci Adv 4:eaao4502
Simpson, Eric L; Villarreal, Miguel; Jepson, Brett et al. (2018) Patients with Atopic Dermatitis Colonized with Staphylococcus aureus Have a Distinct Phenotype and Endotype. J Invest Dermatol 138:2224-2233
O'Neill, Alan M; Gallo, Richard L (2018) Host-microbiome interactions and recent progress into understanding the biology of acne vulgaris. Microbiome 6:177
Berdyshev, Evgeny; Goleva, Elena; Bronova, Irina et al. (2018) Lipid abnormalities in atopic skin are driven by type 2 cytokines. JCI Insight 3:

Showing the most recent 10 out of 41 publications